ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Metrics to compare | 0RQE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0RQEPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.8x | −3.0x | −0.7x | |
PEG Ratio | 0.01 | −0.04 | 0.00 | |
Price/Book | −0.8x | 2.6x | 2.6x | |
Price / LTM Sales | 4.2x | 9.0x | 3.4x | |
Upside (Analyst Target) | - | 140.4% | 36.2% | |
Fair Value Upside | Unlock | 3.5% | 4.1% | Unlock |